Analyst: Buy This Penny Stock Before Earnings

Roth Capital's new SRTS price target is lofty

Andrea Kramer
Aug 1, 2018 at 12:03 PM
facebook twitter linkedin


The shares of medical technology concern Sensus Healthcare Inc (NASDAQ:SRTS) are higher today, with help from some bullish analyst attention. Specifically, ahead of the company's turn in the earnings spotlight tomorrow, Aug. 2, Roth Capital launched coverage of SRTS stock with a "buy" rating and $12.50 price target -- a premium of 83% to yesterday's close. At last check, Sensus shares were up 2.4% at $6.97.

SRTS shares have pulled back some since touching a record high of $7.71 in mid-June. However, the stock seems to have found support in the $6.60 area, which acted as a ceiling shortly after Sensus Healthcare's initial public offering (IPO) in mid-2016. Further, this area is roughly double the security's all-time low of $3.38, touched last July.

SRTS stock chart aug 1

SRTS is no stranger to upbeat analyst attention, however, especially considering the shares have added more than 76% in the past year. Currently, all three analysts following the equity deem it worthy of a "buy" rating. Plus, the consensus 12-month price target of $9.75 represents a premium of nearly 40% to the stock's current perch.


A Schaeffer's exclusive!

The Expert's Guide

Access your FREE trading earnings guide for Q3 before it's too late!


  
 

Partnercenter